Federated Hermes, Inc. Kinnate Biopharma Inc. Transaction History

Federated Hermes, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$1.07 - $2.5 $1,201 - $2,807	-1,123 Reduced 65.75%	585 $1,000
Q3 2023 Nov 13, 2023	BUY	$1.38 - $3.31 $2,357 - $5,653	1,708 New	1,708 $2,000
Q4 2022 Feb 13, 2023	SELL	$5.26 - $12.19 $1.62 Million - $3.75 Million	-307,796 Reduced 100.0%	4 $0
Q1 2021 May 13, 2021	BUY	$26.99 - $40.0 $1.56 Million - $2.31 Million	57,800 Added 23.12%	307,800 $9.59 Million
Q4 2020 Feb 12, 2021	BUY	$36.35 - $45.25 $9.09 Million - $11.3 Million	250,000 New	250,000 $9.95 Million

32.9M

94.7K

802K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.